Compare GOODO & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Current Price
Current Price
| Metric | GOODO | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.1B |
| IPO Year | 2003 | 1996 |
| Metric | GOODO | VCEL |
|---|---|---|
| Price | $17.85 | $58.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $65.43 |
| AVG Volume (30 Days) | 6.1K | ★ 836.1K |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | 0.08 | ★ 0.19 |
| Revenue | $161,336,000.00 | ★ $276,259,000.00 |
| Revenue This Year | N/A | $24.98 |
| Revenue Next Year | N/A | $15.37 |
| P/E Ratio | ★ $223.13 | $304.53 |
| Revenue Growth | 8.00 | ★ 16.45 |
| 52 Week Low | $17.49 | $28.95 |
| 52 Week High | $22.20 | $59.75 |
| Indicator | GOODO | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 75.73 |
| Support Level | $17.50 | $31.94 |
| Resistance Level | $18.21 | $59.75 |
| Average True Range (ATR) | 0.21 | 2.60 |
| MACD | 0.07 | 0.84 |
| Stochastic Oscillator | 46.25 | 94.19 |
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.